Method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -168.55% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTEnsysce Biosciences, Inc.'s latest supported as-filed period reports revenue of $1.2M, 15.1% below the comparable as-filed period. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -168.55% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -15.10% · CORE
Level · gp.fundamentals.operating_margin
Raw value -221.28% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 212.29% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 0.16% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -69.4% from the comparable as-filed period.
Net income changed -48.3% from the comparable as-filed period.
Operating income changed -47.2% from the comparable as-filed period.
Operating margin moved -93.64 percentage points from the comparable as-filed period.
Each point keeps the date investors could first observe it and its accession.
ENSC · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001493152-26-040080SEC ↗8-KAug 24, 2026Period Aug 24, 20260001493152-26-039898SEC ↗4Aug 18, 2026Period Apr 23, 20260001493152-26-038866SEC ↗10-QAug 13, 2026Period Jun 30, 20260001493152-26-037817SEC ↗8-KAug 13, 2026Period Aug 13, 20260001493152-26-037794SEC ↗8-K/AAug 6, 2026Period Aug 5, 20260001493152-26-036326SEC ↗8-KAug 6, 2026Period Aug 5, 20260001493152-26-036268SEC ↗8-KTransaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 7, 2026Filed Aug 18, 2026 | GOWER BOB GDirector | Open Market PurchaseDirect | 400,000 | $0 | $198,000 | Form 4 ↗ |
| Apr 23, 2026Filed Aug 18, 2026 | GOWER BOB GDirector | Open Market PurchaseDirect | 508,614 | $0 | $246,169 | Form 4 ↗ |
| Apr 23, 2026Filed Aug 18, 2026 | GOWER BOB GDirector | ConversionDirect | 254,307 | — | — | Form 4 ↗ |
| Mar 2, 2023Filed Mar 6, 2023 | GOWER BOB GDirector | Open Market PurchaseDirect | 90,287 | $0 | $44,087 | Form 4 ↗ |
| Mar 1, 2023Filed Mar 2, 2023 |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Research & development changed +28.5% from the comparable as-filed period.
Revenue changed -15.1% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001493152-26-033360| GOWER BOB GDirector |
| Open Market PurchaseDirect |
| 270,000 |
| $0 |
| $128,979 |
| Form 4 ↗ |
| Feb 28, 2023Filed Mar 2, 2023 | GOWER BOB GDirector | Open Market PurchaseDirect | 109,300 | $0 | $53,371 | Form 4 ↗ |
| Dec 9, 2022Filed Feb 1, 2023 | GOWER BOB GDirector | Open Market PurchaseDirect | 357,143 | $1 | $500,000 | Form 4 ↗ |
| Dec 9, 2022Filed Feb 1, 2023 | GOWER BOB GDirector | Grant Or AwardDirect | 714,286 | — | — | Form 4 ↗ |
| Jun 23, 2022Filed Jun 27, 2022 | Chang William HDirector | Grant Or AwardDirect | 15,000 | — | — | Form 4 ↗ |
| Jun 23, 2022Filed Jun 27, 2022 | Martin Steven RobertDirector | Grant Or AwardDirect | 15,000 | — | — | Form 4 ↗ |
| Jun 23, 2022Filed Jun 27, 2022 | Rauch Lee M.Director | Grant Or AwardDirect | 15,000 | — | — | Form 4 ↗ |
| Jun 23, 2022Filed Jun 27, 2022 | GOWER BOB GDirector | Grant Or AwardDirect | 15,000 | — | — | Form 4 ↗ |
| Jun 23, 2022Filed Jun 27, 2022 | Rosebraugh CurtisDirector | Grant Or AwardDirect | 20,000 | — | — | Form 4 ↗ |
| Jun 23, 2022Filed Jun 27, 2022 | Benton AndrewDirector | Grant Or AwardDirect | 15,000 | — | — | Form 4 ↗ |
| Jun 23, 2022Filed Jun 27, 2022 | Levin AdamDirector | Grant Or AwardDirect | 15,000 | — | — | Form 4 ↗ |
| May 26, 2022Filed May 27, 2022 | Kirkpatrick LynnChief Executive Officer | Open Market PurchaseDirect | 27,000 | $1 | $14,216 | Form 4 ↗ |
| May 25, 2022Filed May 27, 2022 | Kirkpatrick LynnChief Executive Officer | Open Market PurchaseDirect | 70,000 | $0 | $34,083 | Form 4 ↗ |
| Feb 17, 2022Filed May 27, 2022 | Kirkpatrick LynnChief Executive Officer | Grant Or AwardDirect | 200,000 | — | — | Form 4 ↗ |